Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Won Seog Kim, Jake Shortt, Pier Luigi Zinzani, Natalya Mikhaylova, Ana Marin-Niebla, Dejan Radeski, Vincent Ribrag, Eva Domingo Domenech, Ahmed Sawas, Karenza Alexis, Michael Emig, Linta Garcia, Andre Overesch, Kerstin Pietzko, Steven Horwitz

Cancer Res (2023) 83 (8_Supplement): CT024.

https://doi.org/10.1158/1538-7445.AM2023-CT024

Published: 14 April 2023

View article titled, Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Journal Articles

Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Kate Manos, Richard Khor, Geoffrey Chong, Jodie Palmer, Michael MacManus, Colm Keane, Andrew M. Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze Ting Lee, Wendi Lin, Rachel Koldej, Eliza Hawkes

Cancer Res (2021) 81 (13_Supplement): CT208.

https://doi.org/10.1158/1538-7445.AM2021-CT208

Published: 01 July 2021

View article titled, Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Journal Articles

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

Adele Baker, Gareth P. Gregory, Inge Verbrugge, Lev Kats, Joshua J. Hilton, Eva Vidacs, Erwin M. Lee, Richard B. Lock, Johannes Zuber, Jake Shortt, Ricky W. Johnstone

Cancer Res (2016) 76 (5): 1158–1169.

https://doi.org/10.1158/0008-5472.CAN-15-1070

Published: 29 February 2016

View article titled, The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

Includes: Supplementary data

Journal Articles

Abstract 5384: Prolonged survival of the TH-MYCN murine model of high-risk neuroblastoma, in response to the histone deacetylase inhibitor panobinostat, is the result of both apoptosis and differentiation

Kelly Waldeck, Carleen Cullinane, Jake Shortt, Ben Martin, Kerry Ardley, Richard Tothill, Grant McArthur, Paul J. Wood

Cancer Res (2015) 75 (15_Supplement): 5384.

https://doi.org/10.1158/1538-7445.AM2015-5384

Published: 01 August 2015

View article titled, Abstract 5384: Prolonged survival of the TH-MYCN murine model of high-risk neuroblastoma, in response to the histone deacetylase inhibitor panobinostat, is the result of both apoptosis and differentiation

Journal Articles

Abstract 449: Exome sequencing reveals Bcl6 co-repressor (Bcor) as a frequently mutated tumor suppressor gene in Eμ-Myc lymphoma

Marcus P. Lefebure, Richard Tothill, Jason Li, Geoff Matthews, Jake Shortt, Edwin Hawkins, Elizabeth Kruse, Maria Doyle, Gretchen Poortinga, Ross Hannan, Vivian Bardwell, Micah Gearhart, Ricky W. Johnstone

Cancer Res (2014) 74 (19_Supplement): 449.

https://doi.org/10.1158/1538-7445.AM2014-449

Published: 01 October 2014

View article titled, Abstract 449: Exome sequencing reveals Bcl6 co-repressor (Bcor) as a frequently mutated tumor suppressor gene in Eμ-Myc lymphoma

Journal Articles

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

Alison C. West, Stephen R. Mattarollo, Jake Shortt, Leonie A. Cluse, Ailsa J. Christiansen, Mark J. Smyth, Ricky W. Johnstone

Cancer Res (2013) 73 (24): 7265–7276.

https://doi.org/10.1158/0008-5472.CAN-13-0890

Published: 16 December 2013

View article titled, An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

Includes: Supplementary data

Journal Articles

Abstract 4311: Utilising the preclinical Vk*MYC model of multiple myeloma to rapidly and effectively screen novel therapies and their combinations

Geoffrey M. Matthews, Marta Chesi, Marcus Lefebure, Jake Shortt, Kellie Banks, Kym Stanley, David Faulkner, Peter Atadja, Leif Bergsagel, Ricky W. Johnstone

Cancer Res (2011) 71 (8_Supplement): 4311.

https://doi.org/10.1158/1538-7445.AM2011-4311

Published: 15 April 2011

View article titled, Abstract 4311: Utilising the preclinical Vk*MYC model of multiple myeloma to rapidly and effectively screen novel therapies and their combinations

NARROW

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

Abstract 5384: Prolonged survival of the TH-MYCN murine model of high-risk neuroblastoma, in response to the histone deacetylase inhibitor panobinostat, is the result of both apoptosis and differentiation

Abstract 449: Exome sequencing reveals Bcl6 co-repressor (Bcor) as a frequently mutated tumor suppressor gene in Eμ-Myc lymphoma

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

Abstract 4311: Utilising the preclinical Vk*MYC model of multiple myeloma to rapidly and effectively screen novel therapies and their combinations

Email alerts

AACR Journals

Abstract CT024: REDIRECT: A Phase 2 study of AFM13 in patients with CD30-positive relapsed or refractory (R/R) peripheral T cell lymphoma (PTCL)

Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia

Abstract 5384: Prolonged survival of the TH-MYCN murine model of high-risk neuroblastoma, in response to the histone deacetylase inhibitor panobinostat, is the result of both apoptosis and differentiation

Abstract 449: Exome sequencing reveals Bcl6 co-repressor (Bcor) as a frequently mutated tumor suppressor gene in Eμ-Myc lymphoma

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

Abstract 4311: Utilising the preclinical Vk*MYC model of multiple myeloma to rapidly and effectively screen novel therapies and their combinations

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only